Interleukin 12 gene therapy - Regulon

Drug Profile

Interleukin 12 gene therapy - Regulon

Alternative Names: LipoVIL12

Latest Information Update: 30 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regulon
  • Class Antineoplastics; Cytokine genes; Gene therapies; Interleukins
  • Mechanism of Action Immunomodulators; Interleukin 12 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioblastoma

Most Recent Events

  • 30 Sep 2015 Discontinued - Phase-I/II for Glioblastoma in Germany (Parenteral)
  • 30 Sep 2015 Discontinued - Phase-II for Glioblastoma in Greece (Parenteral)
  • 08 Dec 2014 Interleukin 12 gene therapy licensed to In Ovations Holdings
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top